跳至主要内容
临床试验/NCT06050668
NCT06050668招募中2 期

MEND Repair & Recover Clinical Trial

Michael C Willey3 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年6月17日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
60
试验地点
3
主要终点
Concentration and average count of satellite cells, myonuclei, M1, and M2 Macrophages for Type 1 and Type 2 fibers

研究概览

简要总结

This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.

详细描述

This study consists of 7 study visits that occur over 6 months after operative fixation of femoral fragility fracture. Consenting participants will be asked to complete the study assessments/procedures at the time points described below. Patients will be treated with operative fixation of their fracture per standard of care.

Preoperative

  • Mini-Mental State Examination (MMSE-2®): This is a screening tool for cognitive impairment and will be used to determine eligibility for the study.
  • Subjects will be randomized to the intervention arm or control arm in a 1:1 ratio. Subjects randomized to the control arm will receive standard of care nutrition during hospital admission. Subjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care nutrition. Subjects will take the supplement twice daily for 4 weeks after injury. Supplementation will begin within 72 hours of surgical fixation.

Day of Surgery (DOS):

  • Muscle Biopsy: Bilaterial biopsies will be obtained from the superficial vastus lateralis muscle on the injury extremity. Biopsies will be performed by board-certified orthopedic surgeons.
  • Systemic Inflammatory Labs: A sample of about 15 mL of peripheral venous blood will be obtained by trained clinical staff.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hospital inpatient
  • Age ≥ 65 years old on admission
  • Low-energy mechanism of injury
  • Diagnosis of femur fracture (OTA 31, 32, or 33 fracture)
  • Indicated for surgical fixation
  • Able to provide informed consent

排除标准

  • Part of a vulnerable population (ex: Incarcerated, Non-English speaking)
  • Cognitive impairment (MMSE score ≤ 17)
  • Electrical medical implant (ex: Pacemaker/Defibrillator, Left Ventricular Assist Device, Cochlear implant, Insulin pump, Pain medication pumps, Spinal cord stimulator)
  • Non-ambulatory prior to injury
  • Inability to consume an oral diet or allergy to supplement ingredients (ex: milk allergy)
  • Concern for inability to complete follow-up
  • Hemi or total arthroplasty (joint replacement)
  • Patients with a historical diagnosis of chronic kidney disease (CKD)

研究组 & 干预措施

Essential Amino Acid Supplementation

Experimental

Subjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care postoperative nutrition. Subjects will take 1 scoop (26.7g) of supplement twice daily for 4 weeks after injury. Supplementation will begin within 72 hours of surgical fixation. The EAA-based supplement used in this clinical trial is MEND™ Repair and Recover®.

干预措施: Essential Amino Acid Supplementation (Combination Product)

Standard of Care Postoperative Nutrition

No Intervention

Subjects randomized to the control arm of this study will receive no intervention. They will receive standard of care postoperative nutrition.

结局指标

主要结局

Concentration and average count of satellite cells, myonuclei, M1, and M2 Macrophages for Type 1 and Type 2 fibers

时间窗: Day of Surgery, 3 weeks

Biopsy results will provide the counts and averages by Type I and Type II fibers for satellite cells, myonuclei, M1 and M2 macrophages.

Concentration of c-terminal agrin fragments

时间窗: Day of Surgery, 3 weeks

Through serum analysis levels of c-terminal agrin fragment will be measured in ng/mL.

Cross sectional concentration of Type 1 and Type 2 muscle fibers

时间窗: Day of Surgery, 3 weeks

Biopsy results will provide the Type I and Type II muscle fiber cross sectional area in µm2.

Concentration of myostatin, interleukin-6, and tumor necrosis factor alpha

时间窗: Day of Surgery, 3 weeks

Through serum analysis levels of myostatin, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) will be measured in pg/mL.

次要结局

  • Change in skeletal muscle(Postoperative day 1, 3 weeks, 6 weeks, 12 weeks)
  • Measurement of self-reported physical capability(Post operative day 1, 3 weeks, 6 weeks, 12 weeks, 6 months)
  • Measurement of self-reported ability to complete activities of daily living (ADL)(Preoperative, 3 weeks, 6 weeks, 6 months)
  • Measurement of lower extremity functioning in older adults(12 weeks)
  • Assessment of mobility, balance, walking ability, and fall risk in older adults(12 weeks)
  • Assessment of independent or communal living(Preoperative, 3 weeks, 6 weeks12 weeks, 6 months)

研究者

发起方
Michael C Willey
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Michael C Willey

Assistant Professor

University of Iowa

研究点 (3)

Loading locations...

相似试验